AR 2 trial, patients with severe coronary artery
disease, COPD, or poor renal function were considered
ineligible for open repair. Whereas the study has been
criticized for its trial design, EVAR did not affect overall
survival. Two-year survival was 60% and 5-year survival
was 35%.309 De Martino and coworkers assessed survival
after EVAR within the Vascular Study Group of New
England population